Visceral leishmaniasis (VL) is a life-threatening systemic infection caused by protozoa of the genus Leishmania and transmitted by phlebotomine sandflies. Leishmaniases are widespread in most countries in the Mediterranean basin, including Turkey. Leishmania infantum is responsible for VL in Turkey. We previously reported 19 children with VL who were diagnosed during the period of January 2000 ...

visceral leishmaniasis (vl) is usually treated with pentavalent antimonial drugs given alone or in combination with other drugs. the efficacy of these treatments is diminishing, however, and development of alternative treatments has been recommended.we studied 13 patients with leishmaniasis who were unresponsive to meglumine antimonate, at a dose of 20 mg/kg body weight/per day given for 30 day...

GENERIC NAME PAGE Amodiaquine 614 Atovaquone 616 Chloroguanide 615 Chloroquine 613 Dapsone 615 Diloxanide 609 Eflornithine 610 Hydroxychloroquine 614 Iodoquinol 608 Mefloquine 616 Meglumine antimonate 611 Melarsoprol 610 GENERIC NAME PAGE Metronidazole 608 Nifurtimox 610 Paromomycin 609 Pentamidine 609 Primaquine 614 Pyrimethamine 614 Quinine 615 Sodium stibogluconate 611 Suramin 609 Trimethopr...

Cutaneous Leishmaniasis (CL) is a skin infection caused by various species of Leishmania parasites, which is transmitted by infected Phlebotomus sandfly bites. Pentavalent antimonials (meglumine antimoniate and sodium stibogluconate) are used for the treatment of adult CL patients as an effective and safe method. Liposomal amphotericin B is an alternative for the treatment of choice in cutaneou...

Records were reviewed of 82 immunocompetent children (median age, 2. 5 years) from southern Greece who were diagnosed with visceral leishmaniasis from 1986 through 1998. Forty-nine (58%) patients originated from the city of Athens; of them, 46 (94%) lived by hills bordering the city. The median interval from the onset of symptoms to admission was 10 days. Fever and splenomegaly were observed in...

We determined the efficacy of the combination of the topical formulation 15% paromomycin sulfate/12% methylbenzethonium chloride (MBCL) and a short course (7 days) of parenteral meglumine antimonate (pentavalent antimony [Sb]) as treatment of American cutaneous leishmaniasis in Colombian patients. Patients were randomly assigned in unequal allocation (2:1:1:1) to group 1 (topical paromomycin/MB...

SIR—We congratulate Soto and colleagues [1] for their interesting study, because to our knowledge it is the first controlled trial assessing the effect of topical paromomycin/methylbenzethonium chloride (MBCL) in combination with meglumine antimonate as treatment of New World cutaneous leishmaniasis. This study did not show any additional therapeutic effect of the ointment in combination with p...